SlideShare a Scribd company logo
CORONARY: The Coronary Artery Bypass
   Grafting Surgery Off or On Pump
       Revascularization Study

                    Results at 1 Year
                                 André Lamy
                        Population Health Research Institute
                             Hamilton Health Sciences
                               McMaster University
                                Hamilton, CANADA

              on behalf of the CORONARY Investigators

    Disclosures: CORONARY was funded by a grant from the Canadian Institutes
                            of Health Research (CIHR).
Background

• Benefits and risks of performing CABG surgery on
  beating heart (off pump) not clearly established.
• Meta-analyses of 59 trials involving 8961 pts
  – No differences in major CV outcomes except strokes
• ROOBY (1 Year)
  – Primary Outcome: Off-pump is worse (p=0.04)
  – CV Deaths: Off-pump is worse (p=0.03)


                                                         2
CORONARY Trial Organization
• 79 centers in 19 countries
• 4,752 patients recruited between (November 2006
  October 2011)
• Designed, coordinated, managed and data analysed
  and reported by the Population Health Research
  Institute, Hamilton Health Sciences and McMaster
  University in Hamilton, Canada
• The data was monitored by independent DSMB
• Funded by Canadian Institutes of Health Research

                                                     3
Inclusion/Exclusion Criteria
• Inclusion Criteria
   – Isolated CABG with median sternotomy
   – One of the following:
       1.   Peripheral vascular disease
       2.   Cerebrovascular disease
       3.   Renal Insufficiency
       4.   Age ≥ 70 years
       5.   Age 60 -69 with at least one risk factor (diabetes, urgent
            revascularization, smoker, LVEF ≤ 35%)
       6.   Age 55 -59 with at least two of the above risk factors
• Exclusions
   – Additional cardiac procedure planned
   – Contraindications to off-pump or on-pump CABG
   – Emergency or re-do CABG
                                                                         5
Qualifications of Surgeons
• Surgical expertise-based randomization

  – > 2 years of experience as staff cardiac surgeon
                 and
  – > 100 cases of one or both techniques

  – Trainees were not allowed to be primary
    operators

                                                       6
Primary Outcomes
• 1st Co-Primary Outcome
  Composite of total mortality, stroke, non fatal myocardial
  infarction, new renal failure at 30 days post randomization
                   results presented ACC 2012
                   results at 1 year

• 2nd Co-Primary Outcome
  Composite of above outcomes plus repeat coronary
  revascularization over 5 yrs of follow-up (expected 2016)

                                                                7
Baseline Characteristics
                                 OFF-PUMP     ON-PUMP
                                 (n = 2375)   (n = 2377)
Mean Age (years)                    67.6        67.5

Males (%)                           80.0        81.7
Prior MI                            33.8        35.2

Previous Stroke                     6.7          7.8

Peripheral Arterial Disease         8.0          8.2

Congestive Heart Failure            5.9          6.6
Urgent Surgery                      39.5        38.1

Euroscore
   0–2                              28.6        27.8
   3–5                              51.7        54.2
   > 5                              18.1        16.8
                                                           10
Baseline Disease – Pre-op Angiogram

                       OFF-PUMP     ON-PUMP
                       (n = 2375)   (n = 2377)
                            %            %

Left Main                 22.1        20.9

Triple Vessel             56.1        60.4

Double Vessel             18.7        16.4

Single Vessel             3.0          2.1




                                                 11
1st Co-Primary Outcome (1 Year)
                                   Off Pump On Pump   Hazard                 p
                                       %       %       Ratio    95% CI     value
Primary Outcome
                                    12.1     13.3      0.91    0.77-1.07   0.24
Death, Stroke, MI, Renal Failure
Components

   Death                             5.1      5.0      1.03    0.80-1.32

   Stroke                            1.5      1.7      0.90    0.57-1.41

   Non Fatal MI                      6.8      7.5      0.90    0.73-1.12

   New Renal Failure                 1.3      1.3      0.97    0.59-1.60




                                                                                   14
Death/MI/Stroke/New Renal Failure
                        0.20
                        0.15          at 1 Year


                                         On Pump CABG
Cumulative Event Rate




                                         Off Pump CABG
                        0.10




                                             HR 0.91
                        0.05




                                             95% CI 0.77-1.07
                                             p value 0.24
                        0.0




                               0   3     6               9      12

                                                                     15
Other Outcomes at 1 year
                               Off Pump On Pump   Hazard
                                                            95% CI     p value
                                   %       %       Ratio

Cardiovascular Mortality         4.2      4.0      1.03    0.78-1.37    0.83

Angina                           1.0      0.9      1.05    0.58-1.88    0.87

PCI                              1.1      0.8      1.43    0.79-2.57    0.23

Re-do CABG                       0.3     0.04      7.00    0.86-57.0    0.07

PCI/Re-do CABG                   1.4      0.8      1.66    0.95-2.89    0.07

Primary Outcome per Protocol     11.5    13.2      0.86    0.73-1.02    0.08



                                                                               16
Primary Outcome between
                     31 days and 1 Year
                                Off Pump On Pump Hazard                 p
                                    %       %     Ratio    95% CI     value
Primary Outcome
                                  2.6      3.2    0.79    0.55-1.13   0.19
Death/MI/Stroke/Renal Failure
Components
  Death                           2.1      2.3    0.87    0.58-1.31
  Stroke                          0.5      0.6    0.83    0.36-1.92

  Non Fatal MI                    0.2      0.4    0.50    0.15-1.65

  New Renal Failure               0.1      0.2    0.50    0.09—2.71




                                                                              17
Other Outcomes between
                     31 days and 1 Year
                           Off Pump On Pump   Hazard
                                                        95% CI     p value
                               %       %       Ratio

Cardiovascular Mortality     1.5      1.5      1.06    0.65-1.73    0.82

Angina                       0.8      0.7      1.13    0.56-2.26    0.74

PCI                          0.7      0.6      1.15    0.55-2.41    0.72

Re-do CABG                   <0.1      0                            0.99

PCI/Re-do CABG               0.7      0.6      1.22    0.59-2.54    0.59




                                                                           18
Quality of Life




                  19
Neurocognitive Function




                          20
Subgroups (1)




                21
Subgroups (2)




                22
Conclusions
• At 1 Year there was no difference between Off
  pump CABG and On pump CABG:

  – Primary Outcome
  – Individual components of the Primary Outcome
  – Revascularization procedures
  – Quality of Life
  – Neurocognitive functions

                                                   23
Implications


• In experienced hands, both procedures are
  reasonable options based on mid-term
  results




                                              24
Steering Committees
A. Lamy (Co-PI)        P.J. Devereaux   J. Murkin
D.P. Taggart           D. Prabhakaran   R.J. Novick
A.R. Akar              S.E. Fremes      E. Paolasso
A. Avezum              S. Hu            L. Piegas
R. Cartier             F. Lanas         Z. Straka
S. Chocron             P.J. Lopez       S. Yusuf (co-PI)




                                                           25
Final Recruitment by Country
      4752 patients from 79 sites in 19 countries
                           Netherlands (27)
                             Sweden (56)
                         United Kingdom (227)
 Canada (830)
                              France (4)        Czech Republic (298)
                               Italy (48)           Estonia (91)
                                                    Turkey (132)
     USA (68)                                       Ukraine (11)
                                                                       China (781)


                                                           India (1307)


    Colombia (57)

                       Brazil (358)


                                                                                     Australia (29)
       Chile (137)        Uruguay (34)

                     Argentina (257)




                                                                                                      26
27

More Related Content

What's hot

CYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
CYTX Cardiac Cell Therapy Panel Presentation at Biotech ShowcaseCYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
CYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
Cytori Therapeutics, Inc.
 
Cohen MG - AIMRADIAL 2013 - Complex PCI
Cohen MG - AIMRADIAL 2013 - Complex PCICohen MG - AIMRADIAL 2013 - Complex PCI
Iora Health
Iora HealthIora Health
Iora Health
Avado Inc.
 
Mann T 201110
Mann T 201110Mann T 201110
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Now you see them, now you don't: the usefulness of data auditing in EHR devel...
Now you see them, now you don't: the usefulness of data auditing in EHR devel...Now you see them, now you don't: the usefulness of data auditing in EHR devel...
Now you see them, now you don't: the usefulness of data auditing in EHR devel...
Health Informatics New Zealand
 
Benchmarks in Thought Leader Management
Benchmarks in Thought Leader ManagementBenchmarks in Thought Leader Management
Benchmarks in Thought Leader Management
Robert Nauman
 

What's hot (7)

CYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
CYTX Cardiac Cell Therapy Panel Presentation at Biotech ShowcaseCYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
CYTX Cardiac Cell Therapy Panel Presentation at Biotech Showcase
 
Cohen MG - AIMRADIAL 2013 - Complex PCI
Cohen MG - AIMRADIAL 2013 - Complex PCICohen MG - AIMRADIAL 2013 - Complex PCI
Cohen MG - AIMRADIAL 2013 - Complex PCI
 
Iora Health
Iora HealthIora Health
Iora Health
 
Mann T 201110
Mann T 201110Mann T 201110
Mann T 201110
 
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
Rosuvastatina disminuye la incidencia de nefropatía por contraste en paciente...
 
Now you see them, now you don't: the usefulness of data auditing in EHR devel...
Now you see them, now you don't: the usefulness of data auditing in EHR devel...Now you see them, now you don't: the usefulness of data auditing in EHR devel...
Now you see them, now you don't: the usefulness of data auditing in EHR devel...
 
Benchmarks in Thought Leader Management
Benchmarks in Thought Leader ManagementBenchmarks in Thought Leader Management
Benchmarks in Thought Leader Management
 

Viewers also liked

Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Sociedad Latinoamericana de Cardiología Intervencionista
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
Sociedad Latinoamericana de Cardiología Intervencionista
 
DEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVIDEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVI
Sociedad Latinoamericana de Cardiología Intervencionista
 
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Quirofano hibrido por Dr. Gerardo Sela.
Quirofano hibrido por Dr.  Gerardo Sela.Quirofano hibrido por Dr.  Gerardo Sela.
Quirofano hibrido por Dr. Gerardo Sela.
gerardo sela
 
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
CardioTeca
 
Descripción de la Sala de Hemodinamia
Descripción de la Sala de HemodinamiaDescripción de la Sala de Hemodinamia
Descripción de la Sala de Hemodinamia
Sociedad Latinoamericana de Cardiología Intervencionista
 

Viewers also liked (11)

Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
Posible beneficio de la esplerenona en pacientes con infarto agudo de miocard...
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
 
DEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVIDEFLECT I: dispositivo de protección cerebral en TAVI
DEFLECT I: dispositivo de protección cerebral en TAVI
 
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
CENTURY: resultados clínicos del nuevo stent liberador de sirolimus y polímer...
 
Quirofano hibrido por Dr. Gerardo Sela.
Quirofano hibrido por Dr.  Gerardo Sela.Quirofano hibrido por Dr.  Gerardo Sela.
Quirofano hibrido por Dr. Gerardo Sela.
 
Curso Taller De Hemodinamica Y Cardiologia Intervencionista
Curso Taller De Hemodinamica Y Cardiologia IntervencionistaCurso Taller De Hemodinamica Y Cardiologia Intervencionista
Curso Taller De Hemodinamica Y Cardiologia Intervencionista
 
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...
 
Hemodinamia
Hemodinamia Hemodinamia
Hemodinamia
 
Descripción de la Sala de Hemodinamia
Descripción de la Sala de HemodinamiaDescripción de la Sala de Hemodinamia
Descripción de la Sala de Hemodinamia
 
Hemodinamia
HemodinamiaHemodinamia
Hemodinamia
 
Hemodinamia
HemodinamiaHemodinamia
Hemodinamia
 

Similar to Revascularización miocárdica sin bomba; iguales resultados al año que la cirugía con bomba

CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
theheart.org
 
Hamon M_2 201111
Hamon M_2 201111Hamon M_2 201111
Off-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patientsOff-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patients
Sociedad Latinoamericana de Cardiología Intervencionista
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
Muhammad Sanaan
 
Dmt g pday_oct12
Dmt g pday_oct12Dmt g pday_oct12
Dmt g pday_oct12
Trevor Pickersgill
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)
escts2012
 
Accord blood pressure (cushman)
Accord blood pressure (cushman)Accord blood pressure (cushman)
Accord blood pressure (cushman)Trimed Media Group
 
Estenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía IsquémicaEstenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía Isquémica
Sociedad Latinoamericana de Cardiología Intervencionista
 
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
Euro CTO Club
 
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
Petrus Stone
 
Whelton sprint(1)
Whelton sprint(1)Whelton sprint(1)
Whelton sprint(1)
Jose Mejias Melendez
 
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
IACTSWeb
 
Implications of the transfer ami trial for clinical practice
Implications of the transfer ami trial for clinical practiceImplications of the transfer ami trial for clinical practice
Implications of the transfer ami trial for clinical practiceTrimed Media Group
 
Trial to assess chelation therapy (tact) slides
Trial to assess chelation therapy (tact) slidesTrial to assess chelation therapy (tact) slides
Trial to assess chelation therapy (tact) slidesMarilyn Mann
 

Similar to Revascularización miocárdica sin bomba; iguales resultados al año que la cirugía con bomba (20)

Aha lbct
Aha lbctAha lbct
Aha lbct
 
CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
 
Hamon M_2 201111
Hamon M_2 201111Hamon M_2 201111
Hamon M_2 201111
 
Off-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patientsOff-pump versus in-pump CABG in high-risk patients
Off-pump versus in-pump CABG in high-risk patients
 
Medical Sample 23
Medical  Sample 23Medical  Sample 23
Medical Sample 23
 
Ischemia Trial
Ischemia TrialIschemia Trial
Ischemia Trial
 
Dmt g pday_oct12
Dmt g pday_oct12Dmt g pday_oct12
Dmt g pday_oct12
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)
 
Accord blood pressure (cushman)
Accord blood pressure (cushman)Accord blood pressure (cushman)
Accord blood pressure (cushman)
 
Estenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía IsquémicaEstenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía Isquémica
 
Acromegal
AcromegalAcromegal
Acromegal
 
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...
 
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
MI-TLIF - effect of Age, BMI & Comorbidity - 2012-10-06 - SA Neurosurgery Con...
 
S cárdio renal
S cárdio renalS cárdio renal
S cárdio renal
 
Whelton sprint(1)
Whelton sprint(1)Whelton sprint(1)
Whelton sprint(1)
 
Randil
RandilRandil
Randil
 
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020
 
Implications of the transfer ami trial for clinical practice
Implications of the transfer ami trial for clinical practiceImplications of the transfer ami trial for clinical practice
Implications of the transfer ami trial for clinical practice
 
Trial to assess chelation therapy (tact) slides
Trial to assess chelation therapy (tact) slidesTrial to assess chelation therapy (tact) slides
Trial to assess chelation therapy (tact) slides
 
HEART2D TRIAL
HEART2D TRIALHEART2D TRIAL
HEART2D TRIAL
 

More from Sociedad Latinoamericana de Cardiología Intervencionista

POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudosPOLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
Sociedad Latinoamericana de Cardiología Intervencionista
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
Sociedad Latinoamericana de Cardiología Intervencionista
 
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
Sociedad Latinoamericana de Cardiología Intervencionista
 
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico
Sociedad Latinoamericana de Cardiología Intervencionista
 
Tromboaspiración: resistencia de la microcirculación
Tromboaspiración: resistencia de la microcirculaciónTromboaspiración: resistencia de la microcirculación
Tromboaspiración: resistencia de la microcirculación
Sociedad Latinoamericana de Cardiología Intervencionista
 
Stent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcacionesStent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcaciones
Sociedad Latinoamericana de Cardiología Intervencionista
 
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
Sociedad Latinoamericana de Cardiología Intervencionista
 
BVS for BTK
BVS for BTKBVS for BTK
Antiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudoAntiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudo
Sociedad Latinoamericana de Cardiología Intervencionista
 
Polymer-Free DES
Polymer-Free DESPolymer-Free DES
Drug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCIDrug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCI
Sociedad Latinoamericana de Cardiología Intervencionista
 
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
Sociedad Latinoamericana de Cardiología Intervencionista
 
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACIBoletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
Sociedad Latinoamericana de Cardiología Intervencionista
 
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACIBoletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
Sociedad Latinoamericana de Cardiología Intervencionista
 
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACIBoletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
Sociedad Latinoamericana de Cardiología Intervencionista
 

More from Sociedad Latinoamericana de Cardiología Intervencionista (20)

POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudosPOLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
POLAR ACS: plataforma bio absorbible en síndromes coronarios agudos
 
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
ELISA 3: estrategia invasiva precoz vs tardía en pacientes sin supra desnivel...
 
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
THRIVE: La niacina / laropiprant de liberación prolongada. Beneficio cardiova...
 
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
RELAX: Inhibidor de la fosfodiesterasa-5. Insuficiencia cardiaca con función ...
 
Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico Reestenosis intrastent farmacológico con balón farmacológico
Reestenosis intrastent farmacológico con balón farmacológico
 
Tromboaspiración: resistencia de la microcirculación
Tromboaspiración: resistencia de la microcirculaciónTromboaspiración: resistencia de la microcirculación
Tromboaspiración: resistencia de la microcirculación
 
Stent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcacionesStent liberador de sirolimus vs everolimus en bifurcaciones
Stent liberador de sirolimus vs everolimus en bifurcaciones
 
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
¿Qué métodos han confirmado su eficacia para prevenir la nefropatía inducida ...
 
BVS for BTK
BVS for BTKBVS for BTK
BVS for BTK
 
Antiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudoAntiplaquetarios en el síndrome coronario agudo
Antiplaquetarios en el síndrome coronario agudo
 
Polymer-Free DES
Polymer-Free DESPolymer-Free DES
Polymer-Free DES
 
Drug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCIDrug-Eluting Stents for Multivessel PCI
Drug-Eluting Stents for Multivessel PCI
 
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarct...
 
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Ho...
 
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...Cangrelor compared with clopidogrel improves efficiency without increasing bl...
Cangrelor compared with clopidogrel improves efficiency without increasing bl...
 
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
Angioplastias electivas: se pueden realizar en Hospitales con o sin soporte q...
 
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
Oclusión de la orejuela izquierda vs anticoagulación con Warfarina para preve...
 
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACIBoletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 81, Novembro 2012 - Programa Educativo PROEDUCAR SOLACI
 
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACIBoletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
Boletim 79, Setembro 2012 - Programa Educativo PROEDUCAR SOLACI
 
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACIBoletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
Boletin 80, Octubre 2012 - Programa Educativo PROEDUCAR SOLACI
 

Recently uploaded

heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
SwastikAyurveda
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
Suraj Goswami
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
ShashankRoodkee
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
NEHA GUPTA
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 

Recently uploaded (20)

heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Gram Stain introduction, principle, Procedure
Gram Stain introduction, principle, ProcedureGram Stain introduction, principle, Procedure
Gram Stain introduction, principle, Procedure
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Sex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skullSex determination from mandible pelvis and skull
Sex determination from mandible pelvis and skull
 
CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}CDSCO and Phamacovigilance {Regulatory body in India}
CDSCO and Phamacovigilance {Regulatory body in India}
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 

Revascularización miocárdica sin bomba; iguales resultados al año que la cirugía con bomba

  • 1. CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures: CORONARY was funded by a grant from the Canadian Institutes of Health Research (CIHR).
  • 2. Background • Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. • Meta-analyses of 59 trials involving 8961 pts – No differences in major CV outcomes except strokes • ROOBY (1 Year) – Primary Outcome: Off-pump is worse (p=0.04) – CV Deaths: Off-pump is worse (p=0.03) 2
  • 3. CORONARY Trial Organization • 79 centers in 19 countries • 4,752 patients recruited between (November 2006 October 2011) • Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada • The data was monitored by independent DSMB • Funded by Canadian Institutes of Health Research 3
  • 4. Inclusion/Exclusion Criteria • Inclusion Criteria – Isolated CABG with median sternotomy – One of the following: 1. Peripheral vascular disease 2. Cerebrovascular disease 3. Renal Insufficiency 4. Age ≥ 70 years 5. Age 60 -69 with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF ≤ 35%) 6. Age 55 -59 with at least two of the above risk factors • Exclusions – Additional cardiac procedure planned – Contraindications to off-pump or on-pump CABG – Emergency or re-do CABG 5
  • 5. Qualifications of Surgeons • Surgical expertise-based randomization – > 2 years of experience as staff cardiac surgeon and – > 100 cases of one or both techniques – Trainees were not allowed to be primary operators 6
  • 6. Primary Outcomes • 1st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization results presented ACC 2012 results at 1 year • 2nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 2016) 7
  • 7. Baseline Characteristics OFF-PUMP ON-PUMP (n = 2375) (n = 2377) Mean Age (years) 67.6 67.5 Males (%) 80.0 81.7 Prior MI 33.8 35.2 Previous Stroke 6.7 7.8 Peripheral Arterial Disease 8.0 8.2 Congestive Heart Failure 5.9 6.6 Urgent Surgery 39.5 38.1 Euroscore 0–2 28.6 27.8 3–5 51.7 54.2 > 5 18.1 16.8 10
  • 8. Baseline Disease – Pre-op Angiogram OFF-PUMP ON-PUMP (n = 2375) (n = 2377) % % Left Main 22.1 20.9 Triple Vessel 56.1 60.4 Double Vessel 18.7 16.4 Single Vessel 3.0 2.1 11
  • 9. 1st Co-Primary Outcome (1 Year) Off Pump On Pump Hazard p % % Ratio 95% CI value Primary Outcome 12.1 13.3 0.91 0.77-1.07 0.24 Death, Stroke, MI, Renal Failure Components Death 5.1 5.0 1.03 0.80-1.32 Stroke 1.5 1.7 0.90 0.57-1.41 Non Fatal MI 6.8 7.5 0.90 0.73-1.12 New Renal Failure 1.3 1.3 0.97 0.59-1.60 14
  • 10. Death/MI/Stroke/New Renal Failure 0.20 0.15 at 1 Year On Pump CABG Cumulative Event Rate Off Pump CABG 0.10 HR 0.91 0.05 95% CI 0.77-1.07 p value 0.24 0.0 0 3 6 9 12 15
  • 11. Other Outcomes at 1 year Off Pump On Pump Hazard 95% CI p value % % Ratio Cardiovascular Mortality 4.2 4.0 1.03 0.78-1.37 0.83 Angina 1.0 0.9 1.05 0.58-1.88 0.87 PCI 1.1 0.8 1.43 0.79-2.57 0.23 Re-do CABG 0.3 0.04 7.00 0.86-57.0 0.07 PCI/Re-do CABG 1.4 0.8 1.66 0.95-2.89 0.07 Primary Outcome per Protocol 11.5 13.2 0.86 0.73-1.02 0.08 16
  • 12. Primary Outcome between 31 days and 1 Year Off Pump On Pump Hazard p % % Ratio 95% CI value Primary Outcome 2.6 3.2 0.79 0.55-1.13 0.19 Death/MI/Stroke/Renal Failure Components Death 2.1 2.3 0.87 0.58-1.31 Stroke 0.5 0.6 0.83 0.36-1.92 Non Fatal MI 0.2 0.4 0.50 0.15-1.65 New Renal Failure 0.1 0.2 0.50 0.09—2.71 17
  • 13. Other Outcomes between 31 days and 1 Year Off Pump On Pump Hazard 95% CI p value % % Ratio Cardiovascular Mortality 1.5 1.5 1.06 0.65-1.73 0.82 Angina 0.8 0.7 1.13 0.56-2.26 0.74 PCI 0.7 0.6 1.15 0.55-2.41 0.72 Re-do CABG <0.1 0 0.99 PCI/Re-do CABG 0.7 0.6 1.22 0.59-2.54 0.59 18
  • 18. Conclusions • At 1 Year there was no difference between Off pump CABG and On pump CABG: – Primary Outcome – Individual components of the Primary Outcome – Revascularization procedures – Quality of Life – Neurocognitive functions 23
  • 19. Implications • In experienced hands, both procedures are reasonable options based on mid-term results 24
  • 20. Steering Committees A. Lamy (Co-PI) P.J. Devereaux J. Murkin D.P. Taggart D. Prabhakaran R.J. Novick A.R. Akar S.E. Fremes E. Paolasso A. Avezum S. Hu L. Piegas R. Cartier F. Lanas Z. Straka S. Chocron P.J. Lopez S. Yusuf (co-PI) 25
  • 21. Final Recruitment by Country 4752 patients from 79 sites in 19 countries Netherlands (27) Sweden (56) United Kingdom (227) Canada (830) France (4) Czech Republic (298) Italy (48) Estonia (91) Turkey (132) USA (68) Ukraine (11) China (781) India (1307) Colombia (57) Brazil (358) Australia (29) Chile (137) Uruguay (34) Argentina (257) 26
  • 22. 27